Posters

Effectivity of anti-VEGF in treatment of macular edema in retinal vein occlusions (RVO).

Poster Details

First Author: M.Gajdosova SLOVAKIA

Co Author(s):    N. Hromnikova   M. Ondrejkova                          

Abstract Details



Purpose:

To evaluate the efficacy of anti-VEGF in eyes with macular edema (ME) due to RVO

Setting:

OFTAL, Specialised Hospital for Ophtalmology

Methods:

Retrospective analysis of 63 eyes of 63 patients (24 (38%) men, 39 (62%) women), mean age 73,7 years, mean follow up 33,9 (12-84) months, treated with anti-VEGF (bevacizumab, ranibizumab, aflibercept) at least 12 months. Adjunctive treatment with corticosteroids and laser was allowed. We analysed functional (BCVA - ETDRS letters), anatomical (CRT-um) results, adjunctive ME treatments, number of injections, and adverse events.

Results:

We evaluated 18 eyes (28,6%) with CRVO, mean BCVA 46,5 letters and mean CRT 658 µm and 45 (71,4%) eyes with BRVO, mean BCVA 54,7 letters and mean CRT 485 µm. In CRVO group, mean BCVA change was +12,8 letters after 3 months, +13,1 at 12 and +14,9 letters at 24 months (12,4 mean number of injections) Gain more than 15 letters had 50% eyes after 3 months, 50% eyes at 12 and 46% eyes at 24 months. 1 eye lost more than 15 letters. Mean CRT change was -334 µm after 3 months, -186 µm at 12, -310 um at 24 months. At 24 months 38,9% eyes had complete ME regression. In BRVO group mean BCVA change was +12,9 letters after 3 months, +16,6 at 12 and +17,7 letters at 24 months (10,0 mean number of injections) Gain more than 15 letters had 31% eyes after 3 months, 31% eyes at 12 and 26% eyes at 24 months. We did not record any eye with the loss more than 15 letters . Mean CRT change was -186 µm after 3 months, -184 µm at 12, -198 µm at 24 months. At 24 months 37,8% eyes had complete ME regression.

Conclusions:

Anti-VEGF treatment of macular edema in RVO is very effective and significantly improves the visual prognosis of eyes with this complication.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy